Valvular & structural heart diseaseCohort study
Clinical Impact of In-Hospital Hemoglobin Decline Without Overt Bleeding After Transcatheter Aortic Valve Replacement
- Multicentre cohort study
Authors' conclusion
An in-hospital hemoglobin decrease ≥3 g/dL after TAVR, even in the absence of overt bleeding, was very common and independently associated with worse outcomes.
Study context
- Population
- Transcatheter aortic valve replacement (TAVR) patients without overt bleeding during hospitalization
- Participants
- 9,759 patients
- Exposure
- Minimal, minor or major in-hospital hemoglobin decline without overt bleeding after TAVR
- Outcome
- Incidence, predictors and prognostic implications (mortality) of hemoglobin decline without overt bleeding
- Follow-up
- Median 28 months (Q1-Q3: 12-48 months)
Main finding
As reported in the abstract
Hemoglobin decrease without overt bleeding
Adjusted hazard ratio (95% CI)
Major30-day mortality
3.05(1.15–8.96)
Minor1-year mortality
1.42(1.09–1.86)
Major1-year mortality
1.85(1.13–3.03)
- Hemoglobin decrease occurred
- 5,645 patients (57.8%)
Observational data: associations, not effects.
Further findings
Predictors of significant decline
- Female sex, DAPT, CKD and higher baseline hemoglobin increased risk
- P < 0.01 for all
- Radial secondary access protective
- P = 0.001
Original publication
Clinical Impact of In-Hospital Hemoglobin Decline Without Overt Bleeding After Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. Published 24 November 2025. doi:10.1016/j.jcin.2025.10.004
Summarised from the published abstract; every number is checked against it